Evidence map›Paper›PMID 34186311›Full record

ArticleStem cell research2021

Non-permissive SARS-CoV-2 infection in human neurospheres.

Carolina da S G Pedrosa, Livia Goto-Silva, Jairo R Temerozo, Leticia R Q Souza, Gabriela Vitória, Isis M Ornelas, Karina Karmirian, Mayara A Mendes, Ismael C Gomes, Carolina Q Sacramento and 18 more

Open access · goldAbstract read
In one paragraph

Article in Stem cell research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. iPSC-derived human cortical organoids display profound alterations of cellular homeostasis following SARS-CoV-2 infection and Spike protein exposure.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Neurological complications and infection mechanism of SARS-COV-2.Signal transduction and targeted therapy · 2021
    Review
  15. Review
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 2 countries.

Carolina da S G PedrosaD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Livia Goto-SilvaD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Jairo R TemerozoNational Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
Leticia R Q SouzaD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Gabriela VitóriaD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Isis M OrnelasD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Karina KarmirianD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Mayara A MendesD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Ismael C GomesInstitute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Carolina Q SacramentoImmunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
Natalia Fintelman-RodriguesImmunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
Vinicius Cardoso SoaresImmunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Suelen da Silva Gomes DiasImmunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
José A SalernoD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Teresa Puig-PijuanD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Julia T OliveiraD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Luiz G H S AragãoD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Thayana C Q TorquatoD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Carla VeríssimoInstitute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Diogo BiagiPluricell Biotech, São Paulo, SP, Brazil.
Estela M CruvinelPluricell Biotech, São Paulo, SP, Brazil.
Rafael DariolliPluricell Biotech, São Paulo, SP, Brazil; Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Daniel R FurtadoD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Helena L BorgesInstitute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
Patrícia T BozzaNational Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
Stevens RehenD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil; Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil. Electronic address: srehen@lance-ufrj.org.
Thiago Moreno L SouzaNational Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil. Electronic address: tmoreno@cdts.fiocruz.br.
Marília Zaluar P GuimarãesD'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil. Electronic address: marilia@lance-ufrj.org.
D’Or Institute for Research and Education · BRFundação Oswaldo Cruz · BRUniversidade Federal do Rio de Janeiro · BRBiotech (Brazil) · BRPluriCell (Brazil) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) was initially described as a viral infection of the respiratory tract. It is now known, however, that several other organs are affected, including the brain. Neurological manifestations such as stroke, encephalitis, and psychiatric conditions have been reported in COVID-19 patients, but the neurotropic potential of the virus is still debated. Herein, we sought to investigate SARS-CoV-2 infection in human neural cells. We demonstrated that SARS-CoV-2 infection of neural tissue is non-permissive, however, it can elicit inflammatory response and cell damage. These findings add to the hypothesis that most of the neural damage caused by SARS-CoV-2 infection is due to a systemic inflammation leading to indirect harmful effects on the central nervous system despite the absence of local viral replication.

Indexed as

COVID-19SARS-CoV-2BrainHumansInflammationBrainiPSNeurospheresNew coronavirusSARS-CoV-2

Identifiers

PMID34186311
PMCPMC8236004
OpenAlexW3177036655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.